{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:10:34Z","timestamp":1787825434006,"version":"build-2784847793"},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1055\/a-2368-7090","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T22:46:11Z","timestamp":1743461171000},"page":"412-418","source":"Crossref","is-referenced-by-count":3,"title":["Update: Medikament\u00f6se Therapie bei Colitis ulcerosa"],"prefix":"10.1055","volume":"150","author":[{"given":"Elena","family":"Sonnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis","volume":"12","author":"S Singh","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"08","key":"ref2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"369","author":"BG Feagan","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"ref3","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"BE Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"BG Feagan","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"ref5","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"385","author":"WJ Sandborn","year":"2021","journal-title":"N Engl J Med"},{"issue":"05","key":"ref6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"L Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun Rev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"WJ Sandborn","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"ref8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials","volume":"332","author":"E Louis","year":"2024","journal-title":"JAMA"},{"issue":"26","key":"ref9","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"388","author":"G D\u2018Haens","year":"2023","journal-title":"N Engl J Med"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1055\/a-2271-0994","article-title":"Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2). AWMF-Registriernummer: 021\u2013009","volume":"62","author":"T Kucharzik","year":"2024","journal-title":"Z Gastroenterol"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"R Panaccione","year":"2014","journal-title":"Gastroenterol"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study","volume":"21","author":"A Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/ddg.14508","article-title":"German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm \u2013 Part 1: Treatment goals and treatment recommendations","volume":"19","author":"A Nast","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"issue":"06","key":"ref14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40264-019-00816-3","article-title":"Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn\u2019s Disease: An Integrated Analysis of Phase II\/III Clinical Development Programs","volume":"42","author":"S Ghosh","year":"2019","journal-title":"Drug Saf"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"S Danese","year":"2022","journal-title":"Lancet"},{"issue":"07","key":"ref16","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial","volume":"119","author":"A Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"SR Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apt.15297","article-title":"Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease","volume":"50","author":"C Ma","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/apt.17379","article-title":"Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease","volume":"57","author":"S Din","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Q Xu","year":"2023","journal-title":"Front Pharmacol"},{"issue":"01","key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn\u2019s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation","volume":"17","author":"J Torres","year":"2023","journal-title":"J Crohns Colitis"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2368-7090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T22:47:33Z","timestamp":1743461253000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2368-7090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":21,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2025,3,31]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2368-7090","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}